bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.com

by · The Markets Daily

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE – Free Report) in a report issued on Friday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on BLUE. Wells Fargo & Company reduced their price target on shares of bluebird bio from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 25th. Barclays decreased their price target on bluebird bio from $80.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Bank of America lowered bluebird bio from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $60.00 to $10.00 in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. downgraded bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $49.14.

Read Our Latest Research Report on BLUE

bluebird bio Price Performance

bluebird bio stock opened at $8.50 on Friday. The stock’s fifty day moving average price is $8.53 and its two-hundred day moving average price is $13.68. The firm has a market cap of $82.64 million, a PE ratio of -4.55 and a beta of 0.72. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a one year low of $5.80 and a one year high of $38.40.

bluebird bio (NASDAQ:BLUE – Get Free Report) last posted its quarterly earnings results on Friday, September 27th. The biotechnology company reported ($8.40) EPS for the quarter, missing analysts’ consensus estimates of ($8.00) by ($0.40). The company had revenue of $16.10 million during the quarter, compared to analyst estimates of $16.09 million. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. As a group, research analysts expect that bluebird bio will post -1.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Allegheny Financial Group LTD acquired a new position in bluebird bio in the 2nd quarter valued at approximately $25,000. Verition Fund Management LLC bought a new position in bluebird bio during the 3rd quarter worth $42,000. SG Americas Securities LLC lifted its holdings in bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after buying an additional 74,185 shares during the period. Captrust Financial Advisors grew its position in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 184,605 shares during the period. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

(Get Free Report)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

See Also